

AMENDMENT

Kindly amend the present invention, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows.

IN THE CLAIMS:

Kindly amend the claims, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, to read as follows:

1-20. (Canceled)

21. (Previously Presented) A method for inducing in a feline host an immunological response against feline immunodeficiency virus comprising administering to the feline host at least one naked plasmid wherein the plasmid contains and expresses *in vivo* in a feline host cell nucleic acid molecule(s) having sequence(s) encoding feline immunodeficiency virus env protein, or gag protein, or pro protein, or gag and pro proteins, or env and gag and pro proteins.

22. (Previously Presented) The method according to claim 21 which comprises administering to the feline host a naked plasmid wherein the plasmid contains and expresses *in vivo* in a feline host cell nucleic acid molecule(s) having sequence(s) encoding feline immunodeficiency virus env and gag and pro proteins.

23. (Previously Presented) The method according to claim 21 which comprises administering to the feline host a first naked plasmid wherein the first plasmid contains and expresses *in vivo* in a feline host cell a nucleic acid molecule having a sequence encoding feline immunodeficiency virus env protein; and a second naked plasmid wherein the second plasmid contains and expresses *in vivo* in a feline host cell nucleic acid molecule(s) having sequence(s) encoding feline immunodeficiency virus gag and pro proteins.

24. (Previously Presented) The method of claim 21 wherein the naked plasmid further comprises a cytomegalovirus early (CMV-IE) promoter operatively linked to at least one of the nucleic acid molecule(s).

25. (Previously Presented) The method of claim 21 further comprising administering to the feline host a live whole vaccine against a feline pathogen, or an inactivated whole vaccine against a feline pathogen, or recombinant vaccine against a feline pathogen, or a subunit vaccine against a feline pathogen.

26. (Previously Presented) A method for inducing in a feline host an immunological response against feline immunodeficiency virus comprising administering to the feline host at least one naked plasmid wherein the plasmid contains and expresses *in vivo* in a feline host cell nucleic acid molecule(s) having sequence(s) encoding feline immunodeficiency virus env protein, or env and gag and pro proteins.

27. (Previously Presented) The method according to claim 26 which comprises administering to the feline host a naked plasmid wherein the plasmid contains and expresses *in vivo* in a feline host cell nucleic acid molecule(s) having sequence(s) encoding feline immunodeficiency virus env and gag and pro proteins.

28. (Previously Presented) The method according to claim 26 which comprises administering to the feline host a first naked plasmid wherein the first plasmid contains and expresses *in vivo* in a feline host cell a nucleic acid molecule having a sequence encoding feline immunodeficiency virus env protein; and a second naked plasmid wherein the second plasmid contains and expresses *in vivo* in a feline host cell nucleic acid molecule(s) having sequence(s) encoding feline immunodeficiency virus gag and pro proteins.

29. (Previously Presented) The method of claim 26 wherein the naked plasmid further comprises a cytomegalovirus early (CMV-IE) promoter operatively linked to at least one of the nucleic acid molecule(s).

30. (Previously Presented) The method of claim 26 further comprising administering to the feline host a live whole vaccine against a feline pathogen, or an inactivated whole vaccine against a feline pathogen, or recombinant vaccine against a feline pathogen, or a subunit vaccine against a feline pathogen.

31. (Previously Presented) The method of claim 21 or 26 wherein the immunological response is humoral.

32-37. (Cancelled)